News | Magnetic Resonance Imaging (MRI) | August 25, 2015

C4 Imaging Awarded $1.3 Million NIH Grant For Prostate Imaging

The award will help fund the development of an enhanced multi-modality imaging marker 

MRI marker

C4 Imaging LLC today announced it has been awarded a $1.32 Million Phase II Small Business Innovation Research ("SBIR") grant from the National Cancer Institute of the National Institutes of Health ("NIH"). Entitled "Multi-Modality MRI/CT Markers for Improved Assessment of Prostate Cancer," the Phase II SBIR award will help fund the development of an enhanced multi-modality imaging marker based on C4 Imaging's commercially available Sirius MRI Marker.

This is the second NIH SBIR award for C4 Imaging. C4 Imaging has successfully demonstrated a MRI Marker approach for radioactive seed localization that addresses the need to improve treatment assessment for men who undergo prostate brachytherapy. Sirius is FDA approved for implantation in prostate cancer patients being treated with radioactive seeds (brachytherapy). Its function is based on the unique paramagnetic properties of C4 Imaging's proprietary C4 solution. This core technology was awarded a US patent inSeptember 2013, with additional patent protection for further applications awarded in September 2014. An enhanced, multi-modality version of the device will allow clinicians to utilize multiple imaging modalities for optimal anatomical visualization to improve treatment planning and assessment across a range of diseases.

"This phase II SBIR award is a significant achievement for us," said Andrew Bright, president and CEO of C4 Imaging. "It provides over $1 Million to support the further development of our patented C4 technology. With this award, we can now accelerate our plans to develop additional MRI focused products for cancer patients within a large and growing MRI market."

The Phase II SBIR award will support a detailed development program; including product design, validation and manufacture, along with pre-clinical and clinical testing that will be performed in collaboration with the University of Texas MD Anderson Cancer Center.

For more information: www.c4imaging.com

Related Content

ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
U.K.'s NICE Supports Use of Hydrogel Spacer in Prostate Cancer Treatement
News | Patient Positioning Radiation Therapy | September 08, 2017
Augmenix Inc. announced that the National Institute for Health and Care Excellence (NICE) in the U.K. has issued...
Augmenix Announces Medicare Administrative Contractor Palmetto Coverage for SpaceOAR Hydrogel
News | Patient Positioning Radiation Therapy | September 05, 2017
Augmenix Inc. announced that Palmetto GBA LLC — the Medicare Administrative Contractor (MAC) covering North Carolina,...
China FDA Approves Xoft Axxent Balloon Applicators for Early-Stage Breast Cancer
News | Brachytherapy Systems, Women's Healthcare | August 30, 2017
iCAD Inc. announced that the company’s Xoft Axxent balloon applicators have received approval from the China Food...
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
Electronic Brachytherapy Comparable to Mohs Surgery in Early-Stage Non-Melanoma Skin Cancer Treatment
News | Brachytherapy Systems | July 20, 2017
July 20, 2017 — Rates of recurrence in early-stage non-melanoma skin cancer (NMSC) patients were virtually identical
Synergy Radiology Associates Employs UroNav Fusion Biopsy System for Better Prostate Cancer Diagnosis
News | Biopsy Systems | July 17, 2017
Radiologists from Synergy Radiology Associates (SRA) in Houston are using the power of 3-D medical imaging and...
Overlay Init